8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body

Note: This study found no significant biological effects under its experimental conditions. We include all studies for scientific completeness.

Whole Body / General

Tumkaya L, Kalkan Y, Bas O, Yilmaz A

No Effects Found

Authors not listed · 2016

Share:

This colonoscopy preparation study is unrelated to EMF research and appears misclassified in electromagnetic field health databases.

Plain English Summary

Summary written for general audiences

This appears to be a clinical trial abstract about bowel cleansing preparations for colonoscopy procedures, comparing different formulations (N2D, N1D, and 2LPEG) for their effectiveness and safety. The study found similar bowel cleansing efficacy rates between 87-92% across all three preparations, with some differences in adenoma detection rates. This research is unrelated to electromagnetic field (EMF) exposure or health effects.

Cite This Study
Unknown (2016). Tumkaya L, Kalkan Y, Bas O, Yilmaz A.
Show BibTeX
@article{tumkaya_l_kalkan_y_bas_o_yilmaz_a_ce3894,
  author = {Unknown},
  title = {Tumkaya L, Kalkan Y, Bas O, Yilmaz A},
  year = {2016},
  doi = {10.1177/2050640616663689},
  
}
DOI: 10.1177/2050640616663689

Quick Questions About This Study

This appears to be a database classification error. The study examines bowel cleansing preparations for colonoscopy procedures, not electromagnetic field exposure effects. It should be categorized under gastroenterology research rather than EMF health studies.
The research compared three different colonoscopy preparation solutions (N2D, N1D, 2LPEG) and found bowel cleansing success rates between 87-92%. The N2D formulation showed slightly higher efficacy rates and better colon cleansing in the ascending region.
No, this study provides no information about electromagnetic field exposure or health effects. It focuses entirely on medical preparations used to clean the colon before colonoscopy procedures and has no relevance to EMF research.
The study included approximately 275 patients in each treatment group for the primary analysis, with safety data collected from 262-269 patients per group. This represents a substantial clinical trial size for gastroenterology research.
Treatment-related adverse events occurred in 7.6-14.9% of patients across the three preparation groups. The 2LPEG formulation had the lowest rate of related adverse events at 7.6%, while N1D had the highest at 14.9%.